Trial Profile
A Phase I, Multi-center, Non-randomized, Open Label, Drug-drug-interaction Study to Determine the Effect of Multiple Doses of Regorafenib (BAY 73-4506) on the Pharmacokinetics of Probe Substrates of Transport Proteins P-gp (Digoxin; Group A) and BCRP (Rosuvastatin; Group B) in Patients With Advanced Solid Malignant Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary) ; Digoxin; Rosuvastatin
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Bayer
- 17 Apr 2019 Status changed from active, no longer recruiting to completed.
- 15 May 2018 Planned End Date changed from 30 Jun 2018 to 31 Dec 2018.
- 06 Nov 2017 Planned End Date changed from 31 Dec 2017 to 30 Jun 2018.